CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 1 DIABETES (40-42)

DOI: 10.31618/ESU.2413-9335.2019.1.60.40-42

Дата публикации статьи в журнале: 2019/04/21

Название журнала: Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале, Выпуск: 60, Том: 1, Страницы в выпуске: 40-42

Автор: Kostov O.H.
PhD, assistant , Medical University-Plovdiv,

Анотация: According to the International Diabetes dissociation in 2013 the number of patients with diabetes is 382 million, and by 2035 it is expected to grow to 592 million. Cardiovascular diseases (CVD) are long-term complication of T1ZD. While type 2 diabetes mellitus has numerous studies concerning the relationship between CVD and diabetes, the data in type 1 diabetes mellitus have been scarce. The aim of this review is to briefly present recent studies and data on cardiovascular risk. They outline guidelines for major scientific efforts with the possibility of shaping an effective strategy for the prevention of cardiovascular disease and prevent premature disability and death.

Ключевые слова: type 1 diabetes, macrovascular complications,cardiovascular risk,epicardial adipose tissue,

Данные для цитирования: Kostov O.H. . CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 1 DIABETES (40-42) // Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале. Медицинские науки. 2019/04/21; 60(1):40-42. 10.31618/ESU.2413-9335.2019.1.60.40-42

Скачать в формате PDF

Список литературы: 1. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R. Malik RA, Sosenko JM, Ziegler D, Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40:136-154. 2. Ziegler D. Treatment of Diabetic Polyneuropathy. Update 2006. Ann NY Acad Sci. 2006; 1084:250266. 3. Low PA, Nickander KK, Tritschler IIJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes. 1997;46:S38-S42. 4. Nagamatsu M, Nicklander KK, Schmelzer JB, Raya A, Wittrock DA, Trischler HJ, Low PA. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 1995:18:1160-1167. 5. Patrick L. Mercury toxicity and antioxidants: part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury' toxicity. Ahern Med Rev. 2002;7(6):456-71. 6. Suh JH, Moreau R, Heath SH, Hagen TM. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005;10(l):52-60. 7. Chattopadhyay M, Mata M, Fink D. Continuous deltaopioid receptor activation reduces neuronal voltage-gated sodium channel (Navi .7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci. 2008;28:6652- 6658. 8. Idris I, Donnelly R. Protein kinase Cbeta inhi-bition: a novel therapeutic strategy for diabetic microangiopathy. Diabetes Vase Dis. 2006:3:172-178. 9. Cavaletti G, Miloso M, Nicolini G, Scuteri A, Tredici G. Emerging role of mitogen-activated protein kinases in peripheral neuropathies. J Periplt Nerv Syst. 2007; 12:175-194. 10. Hall K, Liu KJ, Sima AA, Wiley JW. Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol. 2001 ;86:760-770. 11. Varkonyi T. Putz Z, Keresztcs K. Martos T. Lengyel C, Stirban A, Jermendy G, Kempler P. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pltarin Des. 2013;19(27):4981-5007. 12. Boulton AJ, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metal) Res Rev. 2013;29(5):327-33. 13. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol. 2004;3(3): 173-89. 14. Tiaka EK, Papanas N, Manolakis AC, Maltezos E. The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers, hit J Burns Trauma. 2011; 1 (I ):68-76. 15. Bril V, Hirose T, Toniioka S, Buchanan R; Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care. 2009:32(7): 1256-60. 16. Schcmtnel KE, Padiyara RS, D‘SouzaJJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review ../Diabetes Complications. 2010;24(5):354-60. 17. Bansal D, Badhan Y, Gudala K, Schilano F. Ruboxistaurin for the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review of Randomized Clinical Trials. Diabetes Metab J. 2013;37(5):375-384. 18. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M. Baker JR, Kcech AC: FIELD study- investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mcllitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009:373(9677): 1780-8. 19. Snell EE, Strong FM, Peterson WII. Growth factors for bacteria. VI: Fractionation and properties of an accessory factor for lactic acid bacteria. Biochem J. 1937:31 (10): 1789-1799. 20. Reed LJ, DeBusk BG, Gunsalus IC, Horn- bcrger CS Jr. Cristalline alpha-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Science. 1951; 114(2952):93-94.